Sanofi (NASDAQ:SNY) Shares Gap Up – Time to Buy?

Sanofi (NASDAQ:SNY)’s share price gapped up prior to trading on Friday . The stock had previously closed at $52.05, but opened at $53.90. Sanofi shares last traded at $53.57, with a volume of 697,275 shares traded.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Finally, Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Up 4.4 %

The firm’s 50 day moving average price is $56.08 and its two-hundred day moving average price is $51.75. The firm has a market capitalization of $137.63 billion, a PE ratio of 27.31, a P/E/G ratio of 1.40 and a beta of 0.60. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.95 EPS. As a group, research analysts forecast that Sanofi will post 4.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Sanofi

A number of institutional investors have recently made changes to their positions in the business. Boston Partners increased its stake in shares of Sanofi by 0.3% in the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after buying an additional 33,657 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares in the last quarter. Mondrian Investment Partners LTD lifted its position in shares of Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after purchasing an additional 1,190,141 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.